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Abstract
Rodent models of focal cerebral ischemia are essential tools in experimental stroke research. They
have added tremendously to our understanding of injury mechanisms in stroke and have helped to
identify potential therapeutic targets. A plethora of substances, however, in particular an
overwhelming number of putative neuroprotective agents, have been shown to be effective in
preclinical stroke research, but have failed in clinical trials. A lot of factors may have contributed
to this failure of translation from bench to bedside. Often, deficits in the quality of experimental
stroke research seem to be involved. In this article, we review the commonest rodent models of
focal cerebral ischemia - middle cerebral artery occlusion, photothrombosis, and embolic stroke
models - with their respective advantages and problems, and we address the issue of quality in
preclinical stroke modeling as well as potential reasons for translational failure.
Introduction
Ischemic stroke is a common disease that is one of the
major causes of death and disability worldwide, as well as
being a significant economic burden. Given an aging pop-
ulation, ischemic stroke is projected to become even more
important in the future [1]. Animal stroke models have
shed light on the pathophysiology of ischemic stroke [2]
and numerous potential targets for stroke therapy have
been identified. As of 2006, a total of 7,554 results of
1,082 putative neuroprotective interventions in experi-
mental stroke have been published [3]. The translation of
these results from bench to bedside, however, has been
overall disappointing. To date, thrombolytic therapy
using recombinant tissue plasminogen activator is still the
only effective pharmacological treatment in acute
ischemic stroke [4]. Many factors have been discussed that
may have contributed to the lack of concordance of pre-
clinical and clinical study results. Inappropriate conduct
of preclinical research (especially insufficient quality) as
well as suboptimal design of clinical trials (especially
patient selection criteria and clinical evaluation) have
been identified [5]. Lessons from translational failures led
to the Stroke Therapy Academic Industry Roundtable
(STAIR) conferences of academic and industrial experts
from which recommendations and standard operating
procedures for preclinical and clinical stroke research have
been devised [6-10]. Ongoing deficits in experimental
stroke research have been intensely discussed and ana-
lyzed, and additional useful recommendations for quality
improvement have been published [11-15]. In this review
article, the commonest rodent models of focal ischemic
stroke and their respective advantages and disadvantages
are presented and critically discussed with a focus on qual-
ity issues and translational problems.
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Ischemic stroke models
The classification of animal models of ischemic stroke can
be based on a variety of factors such as species, occlusion
mechanisms and stroke etiology, presence or absence of
reperfusion (temporary/transient or permanent
ischemia), the involved vascular territory and infarct dis-
tribution, or a combination of these factors.
A classification of experimental ischemic stroke according
to infarct distribution seems reasonable, and with this
approach global, focal and multifocal ischemia models
can be differentiated [16]. Global cerebral ischemia, a
model of circulatory failure, cannot be regarded as a
stroke model in the strict sense and is beyond the scope of
this review. Focal cerebral ischemia occurs when blood
flow in a specific brain region is critically limited. It is usu-
ally the result of occlusion of a major cerebral artery, such
as the middle cerebral artery. Multifocal ischemia repre-
sents a reduction of cerebral blood flow in multiple
regions and has been described as patchy reduction of cer-
ebral blood flow [16]. Multifocal cerebral ischemia can be
caused by injection of embolus material into a brain-sup-
plying artery.
The etiology of ischemia can be categorized as extravascu-
lar or intravascular [17]. Extravascular mechanisms are
vessel ligation, electrocauterization, or clipping. An inno-
vative method employing an extravascular mechanism is
local application of endothelin-1 adjacent to a brain-sup-
plying artery [18,19] or on the brain surface [20]. Intravas-
cular mechanisms include an intravascular occluding
suture in focal cerebral ischemia and injection of blood
clots and other embolus material in multifocal cerebral
ischemia models.
An overview of cerebral ischemia models is given in Table
1. For ethical and practical reasons, rats and - especially in
transgenic studies - mice are the most widely used labora-
tory animals in preclinical stroke research. In the follow-
ing, we focus on major models of focal stroke in these
rodents.
Major rodent models of focal stroke
Intraluminal thread middle cerebral artery occlusion 
model
The middle cerebral artery occlusion (MCAo) model
using an intraluminal thread was developed by Koizumi
et al. in rats [21], and has subsequently been modified
[22,23] and adapted to mice [24]. Briefly, an occluding
suture or monofilament is advanced via the common
carotid artery into the internal carotid artery towards the
junction of the anterior and middle cerebral arteries. Thus
the middle cerebral artery vascular territory is subjected to
ischemia. The occluding suture may be removed after var-
ious time periods, allowing for reperfusion (transient
MCAo) or it may be left in place permanently (permanent
MCAo).
There are several advantages of this technique: it models
focal infarction in a large vascular territory and does not
require craniotomy. Thus it can be regarded as relatively
simple, though microsurgical skills are required.
Table 1: Overview of experimental stroke models
Cerebral Ischemia Etiology Reperfusion (transient ischemia) or 
permanent ischemia
Examples
Global (complete or incomplete) = model 
of circulatory arrest or severe 
hypotension
Intravascular Transient or permanent Cardiac arrest with or without 
cardiopulmonary resuscitation
Extravascular Transient or permanent Cervical compression by neck cuff; 
ligation of several brain-supplying 
arteries
Focal Intravascular Transient or permanent Intraluminal thread middle cerebral 
artery occlusion model
Extravascular Transient or permanent Surgical middle cerebral artery 
occlusion models using ligation, clipping, 
electrocauterization etc.; endothelin-1-
induced middle cerebral artery 
occlusion
Multifocal Intravascular Transient (spontaneous lysis or 
thrombolytic therapy possible in blood 
clots) or permanent
Embolization models using blood clots, 
microspheres or other embolus 
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Specific complications of the intraluminal thread MCAo
model have been reported. MCAo may be complicated by
subarachnoid hemorrhage in a substantial number of ani-
mals [25-28]. Other adverse events include ipsilateral ret-
inal injury and consequent visual dysfunction [29],
ischemia in the external carotid artery territory [30,31],
intraluminal thrombus formation [32,33], and inade-
quate MCAo and premature reperfusion [26,27,34]. If the
infarct involves the hypothalamus - as seems to be fre-
quently the case in animals subjected to permanent MCAo
or to longer times of transient MCAo - hyperthermia may
develop as a consequence of thermal dysregulation, lead-
ing to altered stroke outcome [35-37]. Technical modifi-
cations and the use of standardized monofilaments can
reduce the incidence of these complications [28,38,39]. In
line with differences in the technical approach, research-
ers may report tremendously different incidences or may
not produce certain complications in their hands at all
[27]. For example, external carotid artery territory
ischemia, such as temporal muscle necrosis resulting in
impaired outcome (decreased body weight and delayed
recovery), has been reported as frequently as in 50% of
animals [30,31], but has not been confirmed by others
and seems to be related to the use of electrocauterization
for vessel dissection [40]. In mice [25,41-43], but also in
rats [44-46], infarct volumes vary considerably between
different strains and ages, and show a steep relationship to
occlusion time [47]. For example, C57Bl/6 mice have sig-
nificantly larger infarcts than SV129 mice in the perma-
nent MCAo model [25,42], most likely due to the absence
of one or both posterior communicating arteries in many
C57Bl/6 mice [43,47,48]. These are the most widely used
parent strains for the production of transgenic mice.
Moreover, infarct volumes found in different murine
MCAo studies using the same mouse strain and same
MCAo duration can range over a fivefold difference [49].
The different absolute and relative incidences of compli-
cations, as well as minor technical differences, may con-
tribute to the considerable variability observed with the
intraluminal thread MCAo model.
Surgical middle cerebral artery occlusion models
There are also models of MCAo that do not use an intra-
luminal occluding suture, but employ an extravascular
mechanism (for example, ligation, clipping, or electrocau-
terization). These surgical MCAo models require craniot-
omy and incision of the dura. For example, the proximal
middle cerebral artery can be identified and occluded after
removal of the coronoid process of the mandible and
zygoma and opening a burr hole lateral to the foramen
ovale [50]. A more refined method that has been reported
to cause reproducible infarctions is tandem occlusion of
the distal middle cerebral and ipsilateral common carotid
arteries [51]. Disadvantages of the surgical approaches,
however, include technical intricacy, possible impairment
of cerebral blood flow auto-regulation by damage to auto-
nomic nerves, and craniotomy. The latter has been shown
to alter brain temperature, intracranial pressure, and
blood-brain barrier permeability [52,53]. For these rea-
sons, most researchers prefer the intraluminal thread
MCAo method.
Photothrombosis model
In the photothrombosis model originally described by
Watson et al. in rats [54] and later modified for mice [55],
a cortical brain lesion is induced by systemic injection of
a photosensitive dye, such as Rose Bengal, and subsequent
focal irradiation of the skull.
Though some researchers expose the dura or brain surface
prior to illumination, the method does not require crani-
otomy if the light penetrates the skull, and it can in this
case be regarded as minimally invasive. A special advan-
tage of photothrombosis is the high reproducibility of
lesion size and location. It is even possible to determine
the region of irradiation stereotactically and thus selec-
tively induce infarcts in cortical areas representing specific
functions [56]. The technique is relatively simple and
allows high throughput.
The penumbra, however, an important target of many
putative stroke therapeutics, is lacking in photothrombo-
sis, where blood-brain barrier disruption and vasogenic
edema develop within minutes [57,58], though modifica-
tions (ring models) seem to be able to produce a penum-
bra-like lesion edge [59,60]. The mechanism by which
photochemically induced brain lesions develop is
thought to involve vascular endothelial damage, platelet
activation and subsequent thrombotic vessel occlusion
[57,58]. Recently, however, we have shown that the pho-
tothrombotic lesion develops independently of the pres-
ence of functional platelets or plasmatic coagulation [61].
Thus photothrombosis does not reflect vascular-ischemic
brain injury or stroke, but focal brain necrosis seems to be
caused directly and irrespectively of additional endothe-
lial damage leading to local thrombosis. These findings
reveal significant differences in mechanisms of tissue
injury induced by photothrombosis as compared to focal
ischemia induced by MCAo, where platelet activation and
the intrinsic coagulation pathway are instrumental
[62,63]. When evaluating antithrombotic pharmaceuti-
cals to limit tissue injury using the photothrombosis par-
adigm, one should therefore be cautious because ensuing
platelet-containing thrombosis may be present, but may
not be mandatory to induce tissue damage.
Models of embolic cerebral ischemia
The first embolic stroke model was developed in dogs [64]
and has subsequently been adapted to rats [65] and mice
[66]. After extensive methodological modifications andExperimental & Translational Stroke Medicine 2009, 1:8 http://www.etsmjournal.com/content/1/1/8
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novel technical developments, various experimental mod-
els of embolic cerebral ischemia exist today. Endothelial
injury of large vessels, for example by irradiation of the
common carotid artery after administration of a photo-
sensitive dye [67], leads to local thrombus formation and
embolic stroke in the distal vascular territory. Other stroke
models use embolic materials, such as polyvinyl com-
pounds, latex microspheres, or blood thrombi that are
prepared ex vivo and injected into the common carotid
artery [68-70] or into the proximal middle cerebral artery
[66,71-73]. Thrombus formation can also be induced at
the origin of the middle cerebral artery by local thrombin
injection [74].
The main advantages of embolic stroke models are their
pathophysiological relevance - embolic vessel occlusion is
the most frequent cause of ischemic stroke in humans -
and, if blood-borne thrombi are used, the possibility to
test thrombolytic compounds. Those models not placing
emboli directly in the proximal middle cerebral artery,
however, often show high variability of infarct location,
distribution, and size (multifocal stroke model). Sponta-
neous lysis of thrombi can occur and is difficult to assess.
Moreover, placement or induction of emboli in the prox-
imal middle cerebral artery is technically demanding. A
common complication, especially in mice, is subarach-
noid hemorrhage, reported in about 40% of mice [66]. In
emboligenic endothelial lesions of the common carotid
artery, lesion type (endothelial denudation versus photo-
thrombosis) may determine the fibrin content of the
thrombi, and thus their embolic potential [75].
As most experimental stroke models address the anterior
circulation, models of vertebrobasilar occlusion are sparse
and have been developed in larger animals such as rab-
bits, cats, and dogs. Recently, however, the autologeous
thromboembolic stroke model [68] has been adapted to
the posterior (vertebrobasilar) circulation in rats [76]
allowing the study of stroke pathophysiology in the brain-
stem and cerebellum that may differ from the situation in
the anterior circulation.
Potential reasons for translational failures and 
proposed actions
Species differences
There are, of course, significant physiological, neuroana-
tomical and metabolic differences between humans and
small rodents, which are the most widely used experimen-
tal animals in preclinical stroke research. For example,
small rodents usually require higher drug doses on a mg/
kg body weight basis for a similar effect than larger mam-
mals [77]. Thus, effective doses derived from preclinical
stroke studies in small rodents cannot simply be trans-
ferred to the situation in humans, even if adjusted for
body weight. Dose-response curves in laboratory animals
and in humans can be helpful to address this problem.
Moreover, it should be kept in mind that mice and rats are
lissencephalic. Therefore, if a drug has been effective in
preclinical stroke studies in small rodents, it is recom-
mended to reproduce the result in higher species (in par-
ticular non-human primates; for review, see Fukuda and
del Zoppo [78]) prior to the initiation of clinical trials [6].
These animals are gyrencephalic and more closely resem-
ble the situation in humans.
Strain differences
Strain differences in mice [25,41-43] and rats [44-46]
must not be underestimated and imply that results in one
strain may not necessarily be reproducible in another
strain. The profound genetic differences and phenotypic
variance between mouse strains can explain that certain
isogenic strains poorly mimic human disease or even that
the effects of a targeted mutation are overshadowed,
which has raised concern about the common practice of
using a single mouse strain, mostly C57BL/6, to address
many questions [79]. In transgenic studies in particular,
not only the single gene mutation but also the genetic
background must be taken into account [79]. Thus, pre-
clinical studies of interventions in stroke should include
more than one rat or mouse strain.
Sex, age, and comorbidities
Preclinical stroke experiments are often restricted to juve-
nile male animals to avoid the variability caused by
female hormone cycling. It was assumed that pathophys-
iology and response to therapy seen in male animals
would also apply to the other sex. In various experimental
stroke models, however, young female adult rodents had
smaller infarcts than their male counterparts [80-82]. In
rats, there seems to be a correlation to the estrous cycle,
with high endogenous estradiol levels in proestrus being
correlated with smaller infarcts than low endogenous
estradiol levels in metestrus [83]. In human observational
studies, premenopausal women have a smaller incidence
of ischemic stroke than men; and stroke risk in both gen-
ders increases with age [84].
There is a complex and significant influence of age on
stroke outcome. Most studies have reported more severe
consequences of cerebral ischemia in aged as compared to
young animals. For example, older rats have been shown
to develop larger infarcts [85,86]. Others, however, have
reported contrary results with a more favorable outcome
in aged animals [45,87]. The correlation between age and
brain damage may not be linear [88]. Aging is associated
with microvascular changes in laboratory rodents [89],
and a small decline of cerebral blood flow has been
observed [90].Experimental & Translational Stroke Medicine 2009, 1:8 http://www.etsmjournal.com/content/1/1/8
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Rats suffering from streptozotocin-induced diabetes and
spontaneously hypertensive rat strains have been shown
to develop larger infarcts [45], illustrating the impact of
comorbidities.
Taken together, the influence of species, strain, sex and
age (and, if applicable, comorbidities) on experimental
stroke must be taken into account. Whereas preclinical
stroke research often uses healthy male juvenile rodents, a
considerable number of stroke patients in clinical studies
will be female, elderly, or suffer from comorbidities such
as diabetes, hypertension and atherosclerosis.
Stroke model
Selection of the most appropriate stroke paradigm is criti-
cal. Models requiring craniotomy, such as proximal mid-
dle cerebral artery ligation, are traumatic and do not
mimic human stroke very closely. MCAo by an intralumi-
nal thread and models using blood clot emboli are more
similar to the clinical situation. Because human stroke is
heterogeneous, however, there can be no single ideal
stroke model. The different experimental stroke para-
digms vary with respect to the underlying pathophysio-
logical mechanisms and the size or location of the lesion.
It is thus prudent to choose an approach that matches the
anticipated situation in stroke patients as closely as possi-
ble. For example, thromboembolic models using blood
clot emboli are helpful when the efficacy of thrombolytic
drugs is to be examined. Ideally, the results should be
reproducible in different models of focal ischemic stroke
and a novel substance should be tested both with and
without reperfusion [6].
Not only should the stroke model reflect the clinical situ-
ation, but the mechanism of action of a putative stroke
drug or intervention should also be relevant for human
stroke pathophysiology and, thus, has to be elucidated
prior to the initiation of clinical studies. It is, for example,
important that potential neuroprotective drugs are able to
penetrate the blood-brain barrier. Cerebral ischemia
causes disruption of the blood-brain barrier, but this
occurs only several hours after stroke onset [91].
Anesthesia
For practical and ethical reasons, experimental focal
stroke has to be induced under appropriate anesthesia
and analgesia. Any type of anesthesia, including inhala-
tion anesthesia, can, however, alter stroke outcome [92].
Barbiturates have various side effects including hypother-
mia and may mediate neuroprotection [93,94], thus inter-
fering with putatively neuroprotective interventions.
Concern has also been raised about the use of ketamine
that could overestimate the neuroprotective effect of an
intervention [95]. Inhalation anesthesia is superior to
intraperitoneal or intravenous administration of anesthet-
ics concerning the control of the depth of anesthesia [96].
Even if inhalation anesthesia is used, however, animals
under general anesthesia that breathe spontaneously have
been shown to exhibit larger infarct volumes and a higher
variability of physiological parameters than those
endotracheally intubated and mechanically ventilated
[96].
Potential pitfalls may thus be avoided by selection of
appropriate anesthesia. Mechanical ventilation seems to
reduce possible side effects of anesthesia on stroke out-
come best, but may be too laborious to be applied rou-
tinely. Inhalation anesthesia should be preferred to
intravenous or intraperitoneal administration of anesthet-
ics, and it seems prudent to avoid barbiturates and keta-
mine.
Flaws in basic study design
Only a minority of published experimental stroke studies
have reported randomized treatment allocation and
blinding of investigators [15]. In a metaepidemiologic
approach examining 13 meta-analyses of experimental
stroke studies, those studies with unblinded induction of
ischemia reported considerably greater effects than
blinded studies demonstrating bias in the design of pre-
clinical stroke studies [97]. Thus, basic universal standards
of scientific research such as blinding of investigators
should be strictly followed in modeling cerebral ischemia.
This should also include confirmation of results by differ-
ent independent laboratories prior to the initiation of
clinical studies.
Therapeutic time window
There is a therapeutic time window in ischemic stroke
[98]. It is defined as the time interval during which an
intervention can lead to partial or total recovery by resto-
ration of perfusion (reperfusion window) or by protection
of penumbra tissue from necrosis (neuroprotective win-
dow). It has also been noted that a rigid and universal
time window for acute stroke therapy does not exist and
that the specific pathophysiological state must be taken
into account to assess the individual therapeutic potential
[99].
The therapeutic time window in ischemic stroke may dif-
fer critically between species, and, in addition, depends
on the mechanism of drug action and is influenced by fac-
tors such as temperature or collateral circulation. The time
point at which a certain drug is administered during
stroke development should thus be carefully selected and
has to balance maximum efficacy on the one hand and
clinical applicability on the other hand. Early drug admin-
istration, or even pretreatment, is usually the most prom-
ising approach regarding efficacy [100], whereas for
routine clinical practice it is desirable to develop drugsExperimental & Translational Stroke Medicine 2009, 1:8 http://www.etsmjournal.com/content/1/1/8
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that are still effective several hours, or even days, after
stroke onset. To address these problems, in-depth phar-
macokinetics in experimental animals and, if possible, in
humans should be determined and compared.
Physiological variables
Physiological parameters can profoundly influence infarct
development and outcome after ischemic stroke. Severe
hyperglycemia has been shown to be detrimental and is
associated with larger infarcts in animal stroke models
[45,101]. A study using insulin after cerebral ischemia in
rats found optimal blood glucose levels at approximately
6 to 7 mM and adverse effects of hypoglycemia below 3
mM [102].
Brain temperature can also have a pronounced influence
in experimental stroke [103]. An interesting example to
illustrate the importance of temperature is the story of
MK-801, an N-methyl-D-aspartate receptor antagonist.
Several studies had shown neuroprotective efficacy of N-
methyl-D-aspartate receptor antagonists in experimental
stroke [104-107]. For MK-801 in particular, promising
results from studies in the gerbil had been published
[108,109]. It was, however, observed that animals devel-
oped prolonged hypothermia following treatment with
MK-801. In 1990, researchers studied the effects of (a)
MK-801 administration, (b) MK-801 administration in
animals kept normothermic, and (c) hypothermia with-
out drug administration [110,111]. Significant and simi-
lar effects were only found in (a) and (c). Thus it was
demonstrated that the beneficial effects of MK-801 in
experimental stroke, previously thought to be mediated
by a specific mechanism involving N-methyl-D-aspartate
receptor antagonism, could in fact be explained by hypo-
thermia. Hypothermia can not only reduce infarct size,
but may also alter infarct distribution [112].
Since arterial blood pressure determines the size of the
area where cerebral blood flow is reduced, induced hypo-
tension in animals subjected to focal cerebral ischemia
may cause larger infarcts [113]. In line, induced hyperten-
sion during [114] and after [115] an episode of focal cer-
ebral ischemia has been shown to ameliorate infarct size.
In the rat intraluminal thread MCAo model, dependency
of damage on blood pressure and on MCAo duration has
been demonstrated [116]. Of course, the level of arterial
blood gases (pO2, pCO2) and pH [96,117,118] can also
influence the development of experimental stroke, but
though these parameters are often monitored, it seems
that their impact has not been studied systematically and
extensively in rodent focal cerebral ischemia models.
Given the impact of physiological variables such as body
and in particular brain temperature, blood pressure, pH,
blood gases, and glucose levels on stroke initiation, devel-
opment and outcome, it can be helpful to monitor these
parameters. To avoid prolonged operation times, how-
ever, recording of all relevant physiological variables in
each individual animal may not be feasible. Except for
experiments modeling comorbidities such as hyperten-
sion or diabetes, physiological variables should usually be
kept within normal limits. By any means, special care
must be taken to prevent hypothermia during and after
surgery. For this purpose, heating pads, heated water
baths, closed chambers with heating fans, and heating
lamps are available and should be used routinely [119].
Outcome analysis
The outcome analysis should include infarct size, histol-
ogy, mortality rate and frequency of complications such as
subarachnoid hemorrhage, and functional (behavioral,
motor and cognitive) scores. Since morphologically intact
tissue does not always imply intact function and does not
exclude delayed lesion development [120,121], end-
points should not be restricted to infarct size, but func-
tional and neurological evaluation should also be
performed. Moreover, histological, biochemical, and
molecular endpoints should be studied to address the
multiple spatially and temporally distributed molecular
and cellular changes in the infarct core and penumbra that
occur after focal cerebral ischemia [122]. Especially if tis-
sue size varies (for example, due to extensive brain
edema), infarct volumes or long-term atrophy should not
be determined as absolute values (mm3), but as relative
measures (percentage of the contralateral hemisphere)
[116]. The extent of the lesion and functional deficits may
change over prolonged time periods [123], whereas the
duration of preclinical experiments is usually limited. It
can thus be helpful to extend the time frame and study
long-term outcome. An elegant way to study the kinetics
of infarct development and to scan for possible hemor-
rhagic transformation, for example after therapeutic inter-
ventions, is the serial use of magnetic resonance imaging
in individual animals [62,63]. Magnetic resonance imag-
ing in laboratory animals subjected to experimental stroke
can even detect diffusion/perfusion mismatch [124] or
provide information on the metabolic state [125]. Mortal-
ity rate and frequency of complications should not only
be recorded, but information should also be given on
excluded animals. The exclusion of certain animals from
the outcome analysis may completely alter results [11].
Deletion of outlier data can be reasonable, but exclusion
and inclusion criteria have to be defined a priori.
Publication of preclinical stroke studies
It has been demonstrated that publication bias is evident
in clinical stroke trials [126]. To address this problem, it
has been suggested that all clinical trials should be regis-
tered and published irrespective of outcome. For a candi-
date neuroprotective drug, nicotinamide, it has beenExperimental & Translational Stroke Medicine 2009, 1:8 http://www.etsmjournal.com/content/1/1/8
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shown that publication bias also plays a role in preclinical
stroke research: Those investigations published in abstract
form showed a smaller effect of nicotinamide compared
to those published as full articles [127]. This illustrates
that results of preclinical stroke trials, whether positive or
negative, should be completely reported and presented to
the scientific community. If electronic journals are used,
journal space must not be a limiting factor precluding the
publication of negative results [128]. To reduce the risk of
translational failure, all relevant information on preclini-
cal studies should be available in peer-reviewed print or
electronic journals when planning the design of clinical
trials.
Coordination of preclinical and clinical research
Evidently, animal models of human diseases cannot be
more than an approximation to the situation in humans
and are always limited by nature. In experimental stroke
models, variables that influence the development of the
ischemic brain lesion are controlled to ensure homogene-
ity, reliability and reproducibility of the results. These fac-
tors include age and sex of the animals studied,
physiological parameters, and the experimental protocol.
In contrast, patient selection criteria in clinical studies
cannot achieve similar homogeneity as in preclinical
experiments. Perhaps extreme homogeneity would not
even be desirable, given that study results must be mean-
ingful for everyday clinical practice. Study patients may
differ in type, location and development of the ischemic
stroke lesion, age, sex, comedication, comorbidities, phys-
iological parameters, and time of application of the study
medication. To account for the heterogeneity, large num-
bers of patients have to be included in clinical trials [129].
Although these problems cannot be completely circum-
vented, they may be ameliorated by appropriate coordina-
tion of preclinical and clinical research. The design of
basic investigations should consider future translation to
the clinic from the very beginning. Conversely, if experi-
mental treatment has been effective, clinical trials should
adhere as closely as possible to the conditions under
which the preclinical data were collected. There is evi-
dence that this has been neglected in the past: of more
than 1,000 potential neuroprotective drugs studied in ani-
mals as of 2006, at least 114 had been tested in acute
stroke patients, yet, interestingly, those drugs studied in
humans were not those that had shown superior efficacy
in animal studies [3].
Heterogeneity of patients in clinical stroke studies can be
taken into account at the level of preclinical stroke
research. Protocols solely using juvenile male animals
may produce more homogeneous and robust results.
Prior to the initiation of clinical studies, however, it seems
to be prudent to perform additional experiments in
female and aged animals or in strains bearing vascular risk
factors such as obesity, hypertension, or diabetes. Indeed,
it has been demonstrated that the use of healthy animals
instead of animals with comorbidities overstates the
effects of interventions in experimental stroke research
[97].
Considerations and proposed actions for the design of
preclinical stroke studies from this review are summarized
in Appendix 1. They overlap and partly extend the STAIR
recommendations for preclinical stroke drug develop-
ment [6,13,14] and are intended to help avoiding proce-
dural pitfalls and translational problems. It seems
unlikely that there is one "ideal" preclinical stroke study
evaluating a stroke drug or intervention comprehensively.
Usually, several different experiments will address differ-
ent issues.
Summary
The presence of intact blood-perfused and then temporar-
ily or permanently occluded vasculature is essential for
the study of ischemic stroke. Research in healthy human
subjects or in stroke patients is very limited. Moreover
human stroke may be very heterogeneous; there may be
many confounding variables, and it may not be possible
to assess physiological and outcome parameters rigor-
ously enough. Therefore, animal models, and in particular
rodent models, play a pivotal role in stroke research in
addition to in vitro techniques such as brain slices, tissue
and cell culture. Rodent models of focal cerebral ischemia
have added tremendously to our understanding of the eti-
ology and pathophysiology of ischemic stroke. The trans-
lation of therapeutic approaches from the animal model
to patient care, however, has been less fruitful. With the
notable exception of intravenous thrombolysis with tissue
plasminogen activator [4,130], the overwhelming major-
ity of drugs showing promise in preclinical research have
failed in subsequent clinical trials. All available stroke
models have inevitable shortcomings and problems. Les-
sons to improve preclinical research methodology and to
better coordinate preclinical and clinical stroke research
have been derived and should be followed to reduce the
risk of future translational failures.
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Appendix 1 - Synopsis of considerations and 
proposed actions to improve the design of 
preclinical stroke studies
1) Select species. Small rodents such as mice and rats
should be used initially (advantages: ethics, costs,Experimental & Translational Stroke Medicine 2009, 1:8 http://www.etsmjournal.com/content/1/1/8
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practicability). After promising results in other species,
studies in non-human primates (advantages: gyren-
cephalic, closer to human situation) should be consid-
ered.
2) Select strain. Ideally, results (both positive and neg-
ative) should be confirmed in other strains.
3) Consider animal studies in juvenile male animals
(advantages: homogeneity, reproducibility). Perform
additional studies in female, aged or comorbid ani-
mals (advantage: closer to clinical situation).
4) Select stroke model. The selected stroke model
should be pathophysiologically relevant for the antic-
ipated clinical situation and match the putative mech-
anism of the drug or intervention studied (for
example, embolic stroke model using blood-borne
thrombi for evaluation of thrombolytics). Stroke
models with reperfusion (advantage: more common
in human stroke) should be preferred over permanent
ischemia models, or, ideally, a putative drug or inter-
vention should be evaluated in both transient and per-
manent stroke models.
5) Select anesthetic and anesthesia method. Inhala-
tion anesthesia should be preferred to intravenous or
intraperitoneal drug administration. The potential
interference of anesthetics with the stroke drug or
intervention studied should be considered. In particu-
lar, barbiturates should be avoided.
6) Include basic scientific standards such as randomi-
zation and blinding of investigators; define inclusion
(for example, postoperative neurological score indi-
cating clinical deficit) and exclusion criteria a priori.
7) Determine pharmacokinetics and dose-response
curves. From these, information on dosage and thera-
peutic time window is derived.
8) Monitor and control relevant physiological param-
eters, at least account for the profound effects of brain
temperature.
9) Consider infarct size, functional/neurological
scores, histological, biochemical and molecular evalu-
ation for outcome analysis. The outcome analysis
should at least not be restricted to only infarct size or
histology.
10) Ideally, study both short-term and long-term out-
come. Serial magnetic resonance imaging examina-
tions may be helpful.
11) Elucidate mechanism of stroke drug or interven-
tion studied. The mechanism should be relevant for
human stroke.
12) Consider combination therapy (for example,
putative neuroprotective drug plus thrombolysis).
13) Publish both positive and negative results.
14) Confirm results in other laboratories.
15) Coordinate preclinical and clinical research. The
anticipated clinical situation should be considered in
preclinical study design; clinical studies should adhere
as closely as possible to the conditions in preclinical
studies that showed efficacy.
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